Here are the 10-K annual reports from Origin Materials, Inc. (ORGN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ORGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORGN filings page.
Origin Materials, Inc. filed an amended annual report to add Part III information on directors, executive pay, ownership and auditor fees that was not included in the original Form 10‑K.
The filing also describes a one‑for‑thirty reverse stock split effective March 19, 2026, which consolidated every 30 shares of common stock into one share without changing par value. All share figures in the amendment reflect this reverse split. The company outlines 2025 and 2024 compensation for its three named executives, equity award terms, director compensation, and that six of seven directors are independent under Nasdaq rules. As of March 20, 2026, Origin had 5,425,037 common shares outstanding and a non‑affiliate market value of about $69.5 million as of June 30, 2025.
Origin Materials, Inc. filed its annual report describing a high-growth but financially strained transition to PET closure manufacturing. The company targets a global closures market estimated at $65 billion with mono-material PET caps designed to improve recyclability, shelf life and lightweighting.
As of December 31, 2025, Origin held $53.5 million in cash, cash equivalents and marketable securities, had an accumulated deficit of $287.8 million, and reported a $249.7 million net loss for the year, raising substantial doubt about its ability to continue as a going concern. The company issued an initial $16.7 million tranche of up to $100 million in senior secured convertible notes but may not meet conditions for further tranches.
To regain Nasdaq compliance, Origin executed a 1‑for‑30 reverse stock split effective March 2026; common shares outstanding were 5,425,037 as of March 20, 2026. Management is pursuing strategic alternatives, cutting about $11 million in annual operating expenses, and focusing resources on scaling its CapFormer PET closure lines while suspending its furanics platform.